Mosquirix, a new vaccine for symptomatic malaria approved by the WHO, shows efficacious results in phase two clinical trials. This trial was conducted in Burkina Faso and the efficacy of the novel malaria vaccine candidate R21/Matrix-M was tested in children aged 5 to 17 months. The vaccine showed decent results after three primary doses and a booster shot. Dr. Azra Ghani, a professor at Imperial College London, says that despite all the efforts that are being made to eradicate malaria, it still poses the same burden, resulting in around 640,000 deaths per year globally. Therefore, the results of phase two clinical trials are a great achievement.
Read More from MedicalNewsToday